TD Cowen’s $110 target on BBIO

BBIO Bridgebio Pharma Inc

$66.1 → $110 (+66%) by Oct 2027

Buy · reiterates · said Oct 5, 2026 · 12-month default horizon

Open: judged on the close on Oct 5, 2027

The article this target came from

TD Cowen reiterates Buy on BridgeBio Pharma stock, cites cardiac data

Investing.com · Oct 5, 2026

TD Cowen reiterated a Buy rating and $110.00 price target on BridgeBio Pharma (NASDAQ:BBIO) shares following data presented at the World Muscle Society conference.

TD Cowen’s track record → Bridgebio Pharma Inc →

A fact about what TD Cowen published, as reported by Investing.com, not a recommendation from Dalsna Finance; TD Cowen is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.